← boardnext 2026-11
ATOS
Atossa Therapeutics, Inc.distress 6/10 · elevated risk$2.54+5%today-86% from 52w high
Lead: ER+/HER2- breast cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$32M
Runway
0.9 yrs
Shares 1y
-93%
Price & events
-73.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.5%
1D
+6.3%
1W
+33.7%
1M
-55.7%
3M
-73.5%
6M
-81.0%
1Y
-88.6%
2Y
-95.9%
5Y
-82.2%
All
Overview
- Market Cap
- $21.87M
- Volume
- 3.33K
- 52 Week Range
- $1.75 – $17.70
- Total Shares
- 8.61M
- Float Shares
- 8.58M
- Short %
- 7.06%
- % Held by Insiders
- 1.85%
- % Held by Institutions
- 16.30%
- RVOL
- 0.01x
- Beta
- 1.25
Pipeline stages · 1 programs
(Z)-endoxifen, goserelin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | (Z)-endoxifen, goserelinrare pediatricorphan | Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer | — | recruiting |
Catalyst news & presentations · 7
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)(Z)-endoxifen · Additional IND submissions planned to advance combination strategies and explore opportunities beyond monotherapy and breast cancer.SEC 8-K
- second quarter of 2026readoutPhase 2(Z)-endoxifen · Preliminary data expected for elagolix combination arm.SEC 8-K
- 2026-01-06fda agreement(Z)-Endoxifen · FDA issued a 'Study May Proceed' letter for the (Z)-endoxifen IND in metastatic breast cancer.SEC 8-K
- 2025trial initiationsecondaryPhase 2(Z)-endoxifen · Recruitment for randomized cohort expected to begin in 2025SEC 8-K
- year-end 2025regulatory submissionFiled (NDA/BLA)(Z)-endoxifen · Update on Type C meeting outcome with FDA regarding accelerated development of low-dose (Z)-endoxifen.SEC 8-K
- 2025-11-17fda agreement(Z)-endoxifen · Completed Type C meeting with FDA to clarify regulatory strategy and expedited pathways.SEC 8-K
- December 11, 2024conferencedata presentationsecondaryPhase 2(Z)-endoxifen · Three posters at SABCS 2024SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $22 (+766% upside) · 3 analysts
- 2026-07-07Rodman & RenshawBuy
- 2026-04-10Ascendiant CapitalBuy
- 2026-03-26HC Wainwright & Co.Buy
- 2025-12-08Ascendiant CapitalBuy
- 2025-09-22Ascendiant CapitalBuy
- 2025-06-06Ascendiant CapitalBuy
Competitors — ER+/HER2- breast cancer
- none identified
Recent news
- 2026-07-21Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers - PR Newswire
- 2026-07-19NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The News-Press
- 2026-07-13Price to sales forward of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
- 2026-07-12Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
- 2026-07-10Atossa Therapeutics sends Sandra S Hammer to AACR rare cancer event in Vancouver - Traders Union
- 2026-07-10ATOS Should I Buy - Intellectia AI
- 2026-07-08ATOS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Investor Reaction - Quarterly Profit Report - dars.gov.et
- 2026-07-08Rodman & Renshaw Initiates Atossa Therapeutics(ATOS.US) With Buy Rating, Announces Target Price $12 - Moomoo
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.